Physician profile
Thomas R Young
NPI 1104998194
$5,622.11
in general payments reported to CMS, 2019-2025
38 companies · $521 in 2025
The $521 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $664 · 2021: $1,106 · 2022: $1,176 · 2023: $767 · 2024: $462 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $729.27 | 2019-2025 | Aveir, Mitraclip, Assurity |
| Novartis Pharmaceuticals Corporation | $664.82 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $455.37 | 2019-2025 | Lifevest |
| Glaxosmithkline, LLC. | $373.45 | 2019-2022 | |
| Amgen INC. | $303.57 | 2021-2025 | Repatha, Repatha |
| Astellas Pharma US INC | $278.41 | 2019-2023 | Lexiscan |
| Merck Sharp & Dohme LLC | $247.09 | 2021-2023 | Verquvo |
| Novo Nordisk INC | $239.52 | 2021-2025 | Wegovy |
| Braemar Manufacturing, LLC | $229.07 | 2019 | |
| Pfizer INC. | $214.37 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.02 | 2020-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $186.21 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $181.30 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $175.03 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $162.67 | 2021-2023 | Watchman Access System |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.